| Next 10 |
Ad
SPRC News and Press SciSparc Ltd.
-
Pharmaceutical company SciSparc ( NASDAQ: SPRC ) shares were trading ~3% down pre-market on the announcement of a restructuring plan. The company said it is planning to pursue a restructuring that involves transferring its pharmaceutical activities to a new unit. The company i...
-
SciSparc will examine the possibility of a public listing for its pharmaceutical activity while retaining a controlling interest TEL AVIV, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage...
-
The Company is expected to evaluat e alternatives to address potential short sales issue TEL AVIV, Israel, Jan. 23, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on ...
-
SciSparc ( NASDAQ: SPRC ) said it received approval from Soroka University Medical Center to conduct its clinical study for SCI-210 in patients with autism spectrum disorder (ASD). During 2022, SciSparc had received approvals from the Israeli Ministry of Health and the Ethics Comm...
-
The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 18, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or ...
-
Penny Stocks + News = ? It’s a new week of the New Year, and traders have high hopes for a January rebound. The exciting part about penny stocks , in particular, is they tend to move independently of broader market trends. That is to say, when the stock market is down, there’...
-
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. TEL AVIV, Israel, Jan. 17, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or ...
-
Ethics Committee and Israeli Ministry of Health approval s already received for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), ...
-
Pre-clinical data on rodents indicate that a novel psychedelic molecule created by Clearmind Medicine ( NASDAQ: CMND ) led to improved energy expenditure, better fat utilization, and weight loss of 20%. Rodents treated with MEAI (5-methoxy-2-aminoindane) also had normalization of...
-
SciSparc and Clearmind’s collaboration continues to yield positive outcomes, the latest with Clearmind results for treating obesity and its related metabolic disorders TEL AVIV, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage p...
Stock Information
SciSparc Ltd. Company Name:
SPRC Stock Symbol:
NASDAQ Market:
Get SPRC Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
